The present work will provide new insights into how drugs bind to and activate a family of receptors that are found throughout the central and peripheral nervous systems. These receptors are called Cys-loop receptors, and they are established therapeutic targets for Alzheimer's disease, schizophrenia, Parkinson's disease, pain, epilepsy, ADHD, autism, depression, addiction and more. Using powerful methodologies developed in previous years of the grant, the structures of the receptors can be modified in precise and subtle ways. In particular, the amino acids that are the building blocks of these protein receptors can be specifically replaced with designed, unnatural amino acids. This allows unprecedented control over the functionality present. How these modifications impact the effectiveness of drugs that target the receptor provides key insights into the mechanism of drug action. A key issue to be addressed will be receptor selectivity - how certain drugs are able to target only specific members of a collection of very closely related receptors. The knowledge generated from these studies will be very valuable to efforts to develop new pharmaceuticals to address the many neurological disorders associated with malfunctions of the Cys-loop receptors.
Neurological disorders, including unipolar depressive disorders, bipolar affective disorder, and schizophrenia, present the greatest health hazard to adults in developed countries, according to the World Health Organization Global Burden of Disease assessment. The present work will provide new insights into how drugs bind to and activate a family of receptors found throughout the central and peripheral nervous systems. Malfunctions of these receptors are associated with the full spectrum of neurological disorders, and knowledge generated by this grant will be of great value to efforts to develop new pharmaceuticals to combat these dreaded diseases.
|Mosesso, Richard; Dougherty, Dennis A (2018) A triad of residues is functionally transferrable between 5-HT3 serotonin receptors and nicotinic acetylcholine receptors. J Biol Chem 293:2903-2914|
|Post, Michael R; Tender, Gabrielle S; Lester, Henry A et al. (2017) Secondary Ammonium Agonists Make Dual Cation-? Interactions in ?4?2 Nicotinic Receptors. eNeuro 4:|
|Post, Michael R; Lester, Henry A; Dougherty, Dennis A (2017) Probing for and Quantifying Agonist Hydrogen Bonds in ?6?2 Nicotinic Acetylcholine Receptors. Biochemistry 56:1836-1840|
|Rienzo, Matthew; Rocchi, Angela R; Threatt, Stephanie D et al. (2016) Perturbation of Critical Prolines in Gloeobacter violaceus Ligand-gated Ion Channel (GLIC) Supports Conserved Gating Motions among Cys-loop Receptors. J Biol Chem 291:6272-80|
|Nichols, Weston A; Henderson, Brandon J; Marotta, Christopher B et al. (2016) Mutation Linked to Autosomal Dominant Nocturnal Frontal Lobe Epilepsy Reduces Low-Sensitivity ?4?2, and Increases ?5?4?2, Nicotinic Receptor Surface Expression. PLoS One 11:e0158032|
|Davis, Matthew R; Dougherty, Dennis A (2015) Cation-? interactions: computational analyses of the aromatic box motif and the fluorination strategy for experimental evaluation. Phys Chem Chem Phys 17:29262-70|
|Henderson, Brandon J; Lester, Henry A (2015) Inside-out neuropharmacology of nicotinic drugs. Neuropharmacology 96:178-93|
|Marotta, Christopher B; Lester, Henry A; Dougherty, Dennis A (2015) An Unaltered Orthosteric Site and a Network of Long-Range Allosteric Interactions for PNU-120596 in ?7 Nicotinic Acetylcholine Receptors. Chem Biol 22:1063-73|
|Post, Michael R; Limapichat, Walrati; Lester, Henry A et al. (2015) Heterologous expression and nonsense suppression provide insights into agonist behavior at ?6?2 nicotinic acetylcholine receptors. Neuropharmacology 97:376-82|
|Miles, Timothy F; Lester, Henry A; Dougherty, Dennis A (2015) Allosteric activation of the 5-HT3AB receptor by mCPBG. Neuropharmacology 91:103-8|
Showing the most recent 10 out of 110 publications